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Interferon regulatory factor 7 (IRF-7) is implicated in the regulation of Epstein-Barr virus (EBV) latency.
EBV transforms primary B cells, and the major EBV oncoprotein, latent membrane protein 1 (LMP-1), is
required for the process. LMP-1 both induces the expression of IRF-7 and activates the IRF-7 protein by
phosphorylation and nuclear translocation. Here we report that the expression of IRF-7 is increased in
EBV-immortalized B lymphocytes compared with that in primary B cells. IRF-7 was phosphorylated and
predominantly localized in the nucleus in the immortalized cells. The expression of IRF-7 was detected in 19
of 27 specimens of primary lymphomas of the human central nervous system by immunohistochemical
analysis. The association between LMP-1 and IRF-7 was statistically highly significant for these specimens. An
appreciable amount of the IRF-7 expressed in lymphoma cells was localized in the nucleus. Furthermore, IRF-7
promoted the anchorage-independent growth of NIH 3T3 cells. LMP-1 and IRF-7 showed additive effects on the
growth transformation of NIH 3T3 cells. IRF-7-expressing NIH 3T3 cells formed tumors in athymic mice. Thus,
IRF-7 has oncogenic properties and, along with LMP-1, may mediate or potentiate the EBV transformation
process in the pathogenesis of EBV-associated lymphomas.
Interferon regulatory factors (IRFs) are a small family of
transcription factors with multiple functions. The hallmark of
these factors is a conserved N-terminal DNA binding domain
which mediates binding to the core region of the interferon
(IFN)-stimulated response element and the regulation of IFN-
responsive promoters. The C-terminal portion is variable and
promotes a variety of biologic functions (26, 46, 59). Some
IRFs are involved in oncogenesis. IRF-2 and IRF-4 are proven
oncogenes, and the overexpression of IRF-4 has been impli-
cated in human malignancy (12, 14, 27, 44, 46). Human her-
pesvirus 8 (HHV-8) encodes several viral IRF homologs
(vIRFs), and vIRF1 has been demonstrated to posses onco-
genic potential both in vitro and in vivo (9). HHV-8 is associ-
ated with Kaposi’s sarcoma and has substantial sequence ho-
mology to Epstein-Barr virus (EBV).
IRF-7 was initially identified within the biological context of
EBV latency (60). EBV is a human herpesvirus of increasing
clinical importance and almost certainly triggers two fatal ma-
lignancies in immunosuppressed patients without the necessity
for cofactors; these malignancies are AIDS-associated central
nervous system (CNS) lymphoma and posttransplantation lym-
phoproliferative disorders (reviewed in reference 31). In addi-
tion, EBV infection is intimately associated with the develop-
ment of nasopharyngeal carcinoma (16, 28, 31, 33, 34, 37).
EBV has been implicated in other malignancies, including
Burkitt’s lymphoma, Hodgkin’s disease, and gastric carcinoma
(16, 31, 37).
IRF-7 has multiple functions. IRF-7 may be involved in
switching EBV latency types and in the maintenance of latency
through its regulation of the viral BamHI Q promoter (Qp) for
Epstein-Barr nuclear antigen 1 (EBNA-1), the usage of which
is indicative of viral latency types I and II (16, 37, 56, 57, 60).
In EBV-infected cells, the expression of IRF-7 is linked with
that of latent membrane protein 1 (LMP-1), the principal EBV
oncogene. LMP-1 both induces the expression of IRF-7 and
activates the IRF-7 protein by phosphorylation and nuclear
translocation (57, 58, 62). In addition, IRF-7 mediates the
activation of the cellular transporter associated with antigen
processing 2 (Tap-2) by LMP-1, suggesting that IRF-7 plays an
important role in host immune system regulation (58). More-
over, it participates in a regulatory circuit with LMP-1 in that
IRF-7 up-regulates LMP-1 promoter activity (29). Also, the
IRF-7 promoter itself is activated by IRF-7-containing VAF
complexes induced directly by virus infection as well as by IFN
(30). Apart from its functions in EBV latent infection, IRF-7
has been shown by several laboratories to be induced and to be
a primary activator of IFN genes upon infection with other
viruses, pointing to the importance of IRF-7 in innate cellular
defense mechanisms (2, 22, 32, 52, 61). Finally, IRF-7 is in-
volved in monocyte differentiation processes (20). Thus, it is
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apparent that IRF-7 plays important roles in a variety of bio-
logical processes.
Several lines of evidence suggest that IRF-7 may have on-
cogenic properties. EBV transforms primary B cells into im-
mortalized cell lines and establishes type III latency (16, 37).
The expression and activation of IRF-7 are consistently asso-
ciated with type III latency, which is characterized by an EBV
transformation state in which LMP-1 is expressed (60). LMP-1,
which is required for transformation by EBV in vitro, is con-
sistently related to but not required for the expression of
IRF-7. Based on these associations and the properties of other
IRFs, we reasoned that IRF-7 may have oncogenic properties
and may play a role in viral transformation. In this report, we
provide evidence by the use of both cell culture systems and
human lymphoma tissues that the expression and activation of
IRF-7 are associated with EBV transformation processes and
that IRF-7 by itself appears to have oncogenic potential.
MATERIALS AND METHODS
Cells, plasmids, and antibodies. NIH 3T3 cells were maintained in Dulbecco’s
minimum essential medium supplemented with 10% calf serum. Jijoye is an
EBV-positive Burkitt’s lymphoma cell line (35); four newly transformed lympho-
blastoid cell lines (LCL-1 to -4) were gifts from Kenneth Izumi. These cells were
maintained in RPMI 1640 plus 10% fetal bovine serum. Fresh blood was pur-
chased from a local Red Cross Station. Primary B cells were isolated by the use
of CD19 antibody-conjugated magnetic beads according to the manufacturer’s
recommendations (Dynal Inc.). The isolated B cells were immediately lysed in
2 sodium dodecyl sulfate (SDS) protein loading buffer for Western blot anal-
ysis or were released from the beads for immunostaining experiments (1, 8, 41,
42). An LMP-1 monoclonal antibody (CS1-4) was purchased from Dako. IRF-1,
IRF-2, and IRF-7 antibodies were obtained from Santa Cruz. Purified antibodies
against full-length IRF-7 and the IRF-7A expression plasmid are described
elsewhere (60). An LMP-1-expressing plasmid was made by the introduction of
cDNA sequences into the pCDNA3.1()-hyg mammalian expression vector
(Invitrogen).
NIH 3T3 cell transformation assays. Subconfluent cultures of NIH 3T3 cells
seeded in 60-mm-diameter tissue culture dishes were transfected with 500-ng
aliquots of desired expression plasmids by the calcium phosphate method. Two
days after transfection, the cultures were subcultured into growth medium sup-
plemented with G418 and/or hygromycin to select for drug-resistant stably trans-
fected cell populations. NIH 3T3 cells stably expressing target proteins were
pooled and analyzed for anchorage-independent growth and for tumor forma-
tion in athymic (nu/nu) nude mice.
For anchorage-independent growth assays, single-cell suspensions (5  104
cells per 60-mm-diameter dish) of each cell line were suspended in growth
medium supplemented with 0.3% agar. The appearance of proliferating colonies
of cells was monitored and quantitated for up to 4 weeks.
For tumor formation in nude mice, 106 cells were trypsinized, suspended in
phosphate-buffered saline solution, and then injected subcutaneously into the
flanks of genetically athymic (nu/nu) mice, and the appearance of tumors was
monitored biweekly.
Western blot analysis with ECL. The separation of proteins by SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) was done according to standard meth-
ods. After the proteins were transferred to a nitrocellulose or Immobilon mem-
brane, the membrane was blocked with 5% nonfat dry milk in TBST (50 mM Tris
[pH 7.5], 200 mM NaCl, 0.05% Tween 20) at room temperature for 10 min. It
was then washed briefly with water and incubated with a primary antibody in 5%
milk in TBST for 1 to 2 h at room temperature or overnight at 4°C. After three
rinses with TBST for 10 min each time, the membrane was incubated with the
secondary antibody at room temperature for 1 h. It was then washed three times
with TBST as before, treated with ECL (Amersham) or SuperSignal (Pierce)
detection reagents, and exposed to Kodak XAR-5 film.
Clinical samples. A total of 27 primary CNS lymphomas was collected from
the archives of the Institute of Pathology, Lausanne University, Lausanne, Swit-
zerland. The tumors were histologically and immunohistochemically character-
ized according to the latest World Health Organization Classification of Brain
Tumors (17). The ages of the patients ranged from 27 to 82 years (Table 1). Two
patients suffered from other human immunodeficiency virus type 1 (HIV-1)-
associated opportunistic infections in addition to the CNS lymphoma. Finally, in
two cases, the CNS lymphoma extended through the subarachnoid space.
Histological and immunohistochemical analysis. Formalin-fixed, paraffin-em-
bedded tissues were sectioned into 4-m-thick sections and stained with hema-
toxylin and eosin for routine histological characterization. Immunohistochemis-
try was performed by use of an avidin-biotin-peroxidase complex system
according to the manufacturer’s instructions (Vectastain Elite ABC peroxidase
kit; Vector Laboratories, Inc.). The samples were deparaffinized in xylene and
rehydrated with alcohols, and nonenzymatic antigen retrieval was performed
with 0.01 M sodium citrate buffer (pH 6.0) for 40 min at 95°C. After a cooling
step, peroxidase quenching was performed with methanol–3% H2O2 for 20 min.
The sections were then blocked in 5% normal horse or goat serum for 2 h at
room temperature. The primary antibodies were incubated overnight at room
temperature in a humidified chamber. The primary antibodies used for this study
included two mouse monoclonal EBV LMP-1 antibodies (a cocktail of mono-
clonal antibodies, including clones CS1 to -4 from DAKO, used at a 1:100
dilution, and clone CS1 from Novocastra Laboratories, used at a 1:100 dilution),
a mouse monoclonal antibody for the detection of CD20 (clone L26; DAKO)
(1:200 dilution), a mouse monoclonal antibody for the detection of HIV p24
(clone Kal-1; DAKO) (1:20 dilution), a rabbit polyclonal IRF-7 antibody from
Santa Cruz (1:50 dilution), and a purified rabbit polyclonal antibody against the
full-length IRF-7 protein (1:500 dilution) (60). Biotinylated secondary mouse or
rabbit antibodies were incubated for 1 h at room temperature followed by
incubation with the avidin-biotin complex; finally, the sections were developed
with diaminobenzidine. The slides were counterstained with hematoxylin, dehy-
drated, cleared in xylene, and mounted with Permount (Sigma Laboratories).
For confocal microscopy analysis, CNS specimens were deparaffinized and
fixed in 4% paraformaldehyde. The sections were then blocked in phosphate-
buffered saline solution plus Tween 20 plus 1% bovine serum albumin for 30 min
TABLE 1. Immunohistochemical detection of cellular IRF-7 and






CD79a CD20 CD3 HIV p24 EBV LMP-1 IRF-7
1 47 Female      
2 38 Male      
3 58 Female      
4 62 Female      
5 35 Male      
6 62 Female      
7 38 Male      
8 69 Female      
9 27 Male      
10 42 Male      
11 39 Male      
12 49 Male      
13 77 Female      
14 80 Male      
15 63 Female      
16 60 Male      
17 82 Male      
18 69 Male      
19 67 Male      
20 79 Male      
21 76 Male      
22 72 Female      
23 78 Female      
24 65 Female      
25 86 Male      
26 67 Female      
27 69 Female      
a Diagnoses of primary CNS lymphomas were based on the WHO classifica-
tion of Brain Tumors.
b , negative reactivity; , 1 to 30% of cells were positive; , 31 to 60% of
cells were positive; , 60% of cells were positive. The association between
LMP-1 and IRF-7 is highly significant (R  0.5449; P  0.0033). The association
between HIV p24 and EBV LMP-1 is also highly significant (R  0.8478; P 
0.0001). Multiple regression analysis was done with Statistica 6.1 (StatSoft, Inc.).
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at room temperature. The primary antibodies were incubated for 2 h at room
temperature in a humidified chamber. The secondary antibodies were incubated
for 1 h at room temperature followed by examination by confocal microscopy.
The primary antibodies used for this study included a monoclonal antibody to
LMP-1 (clones CS1 to -4; DAKO), a rabbit polyclonal antibody to IRF-7 from
Santa Cruz, and a purified rabbit polyclonal antibody against the full-length
IRF-7 protein (60). Cy-2-, Cy3-, and Cy5-conjugated secondary antibodies
against mouse or rabbit immunoglobulin G were purchased from The Jackson
Laboratory.
Phosphorylation analysis and immunoprecipitation. CD19-positive primary B
cells and freshly immortalized LCLs were labeled with [32P]orthophosphate for
4 h, washed once with 1 phosphate-buffered saline solution, and lysed in a
buffer containing 0.5% NP-40, 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 5 mM
EDTA, 100 mM NaF, 1 mM sodium orthovanadate, and 1 mM phenylmethyl-
sulfonyl fluoride. The cell lysates were precleared with a preimmune serum and
protein G-agarose beads under gentle agitation at 4°C for 30 min. An IRF-7
antiserum and protein G-agarose were then added, and the lysates were incu-
bated overnight at 4°C. The beads were washed three times with 1 ml of immu-
noprecipitation washing buffer, resuspended in 50 l of SDS-PAGE sample
loading buffer, and boiled for 5 min. The samples were resolved by electrophore-
sis in an SDS-polyacrylamide gel and then transferred onto an Immobilon mem-
brane. The membrane was dried and autoradiographed. After autoradiography,
the membrane was rehydrated with 100% methanol for 30 s and used for
Western blotting to visualize the total amount of IRF-7.
RESULTS
Expression and activation of IRF-7 are associated with EBV
immortalization of lymphocytes. EBV efficiently immortalizes
and transforms primary B lymphocytes into continually grow-
ing LCLs in vitro. LMP-1 is required for this process. We
tested whether the expression of IRF-7 is induced during cell
immortalization. Primary B cells from two individuals were
isolated by the use of CD19 antibody-conjugated magnetic
beads according to an established protocol (1, 8, 41, 42). West-
ern blot analysis was done to compare the expression of IRF-7
in primary and recently EBV-immortalized B cells. As shown
in Fig. 1, a low level of IRF-7 was detected in primary cells, but
highly elevated levels were expressed in all four of the immor-
talized cell lines. In contrast, the expression of IRF-3, the
closest IRF family member to IRF-7 (46), was not associated
with cell immortalization by EBV in vitro. Neither the expres-
sion of IRF-1 nor that of IRF-2 was increased during EBV
transformation (Fig. 1). Although IRF-2 is associated with
EBV type III latency (56), it should be noted that cellular
genes associated with type III latency may or may not be
expressed in EBV-transformed cells. Bcl-2 is induced by
LMP-1 and associated with type III latency (13). However,
Bcl-2 is not associated with EBV transformation (24), and we
confirmed this finding in our system (55).
The activation status of IRF-7 in primary B cells and that in
the newly immortalized LCLs were compared. In primary B
cells, IRF-7 was predominantly expressed in the cytoplasmic
compartment; however, in LCLs, IRF-7 was mainly detected in
the nucleus (Fig. 2A). In addition, IRF-7 was phosphorylated
in the transformed cells, but phosphorylated IRF-7 could not
be detected in primary uninfected B cells under our experi-
mental conditions (Fig. 2B). The phosphorylation and translo-
cation of IRF-7 from the cytoplasm into the nucleus may be
due to the expression of LMP-1 (58), and these results suggest
that the expression and activation of IRF-7 are associated with
EBV transformation.
IRF-7 is expressed in EBV-positive CNS lymphoma cells.
Primary CNS lymphomas occur with a high frequency in pa-
tients with AIDS and in recipients of organ transplants. CNS
lymphomas are currently considered an HIV-defining disease.
EBV has been detected in virtually all AIDS-associated CNS
lymphoma specimens, and the virus is believed to be the pri-
mary causative infectious agent of the disease (10, 21, 38, 39,
43). EBV establishes type III latency in neoplastic lympho-
cytes, in which expression of LMP-1 is frequently detected.
Because these lymphomas resemble in vitro-transformed B
cells, we examined 27 human CNS lymphoma specimens by
histological and immunohistochemical analyses (Table 1). The
tumors were characterized according to the latest World
Health Organization Classification of Brain Tumors (17). The
patients had been diagnosed with CNS lymphoma and pre-
sented without the involvement of any other organ or tissue.
Histologically, the tumors were characterized by abundant ho-
mogeneous neoplastic lymphocytes, located predominantly
within the Virchow-Robin space in a concentric pattern. In the
majority of the cases, the neoplastic cells had infiltrated the
brain parenchyma (Fig. 3A). At a higher magnification, the
neoplastic cells showed pleomorphic, hyperchromatic nuclei
and a scant cytoplasm; mitotic figures and areas of necrosis
were frequently observed (Fig. 3B). In order to characterize
the variety of neoplastic cells, we performed immunohisto-
chemistry with pan-B (CD20) and pan-T (CD3) markers. Ini-
tially, detection of the very specific but less sensitive CD79a
marker was also performed. All of the tumors studied demon-
strated cytoplasmic expression of CD20 and had the concentric
FIG. 1. Expression of IRF-7 is associated with EBV immortaliza-
tion of B lymphocytes in vitro. Primary B cells were isolated from fresh
human blood by the use of CD19 antibody-conjugated magnetic beads.
CD19 is a pan-B cell marker. Lysates from primary B cells and EBV-
immortalized B cells were separated by SDS-PAGE. The expression
levels of IRF-7 and other proteins as indicated were determined by
Western blotting.
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perivascular pattern and brain parenchyma infiltration by neo-
plastic cells (Fig. 3C and D, respectively). The results show that
only B-cell, and not T-cell, lymphomas were analyzed.
We further examined the EBV status and IRF-7 expression
of the CNS lymphomas. LMP-1 was detected by immunohis-
tochemistry in numerous neoplastic lymphocytes in both the
Virchow-Robin space and individual lymphocytes infiltrating
the brain parenchyma (Fig. 3E and F, respectively). Immuno-
histochemistry with IRF-7 antibodies showed a robust immu-
nolabeling of neoplastic lymphocytes (Fig. 3E and F). With this
assay, IRF-7 was detected in 19 of 27 tumor specimens exam-
ined (70.4%). In addition, LMP-1 was detected in 24 of the 27
specimens, and the association between LMP-1 and IRF-7 was
statistically highly significant (R  0.5449; P  0.0033) (Table
1). Due to the fact that high levels of LMP-1 and IRF-7 are
required for detection by immunochemistry, these data
strongly suggest that high levels of LMP-1 are associated with
high levels of IRF-7 in CNS lymphomas. In addition, EBV
LMP-1 was associated with HIV infection, as shown by the
detection of the p24 antigen in the tumor specimens in all but
four cases (Table 1).
IRF-7 is associated with LMP-1-expressing CNS lymphoma
cells. Finally, we used another assay to detect the relationship
between LMP-1 and IRF-7 in CNS lymphomas, namely, dou-
ble immunolabeling followed by confocal microscopy. With
confocal microscopy, IRF-7 was detected in virtually all of the
specimens, as the fluorescence signals could be amplified with
a higher sensitivity. Since primary B cells expressed IRF-7 (Fig.
FIG. 2. Activation of IRF-7 is detected in EBV-immortalized B cells. (A) IRF-7 is predominantly localized in the nuclei of EBV-immortalized
B cells. Primary B cells were isolated from fresh human blood by the use of CD19 antibody-conjugated magnetic beads and were released from
the beads before fixation with paraformaldehyde. The subcellular localization of IRF-7 in newly transformed LCLs and primary B cells was
detected by staining with an IRF-7 antibody and a Cy-2-labeled donkey anti-rabbit secondary antibody, followed by examination by confocal
microscopy. Propidium iodide was used to stain the nuclei. The colors were artificially mounted to facilitate viewing. Blue, nuclei; green, IRF-7.
(B) IRF-7 is phosphorylated in EBV-immortalized B cells. Primary B cells isolated from fresh human blood and EBV-immortalized LCLs were
labeled with [32P]orthophosphate for 4 h. The cell lysates were used for immunoprecipitation with an IRF-7 antibody. The immunoprecipitates
were separated by SDS-PAGE and transferred to a membrane for Western blotting with the IRF-7 antibody, which was done after autoradiography
for the detection of phospho-IRF-7.
12990 ZHANG ET AL. J. VIROL.
1 and 2), the detection of IRF-7 in these B-cell lymphomas was
anticipated. As shown in Fig. 4, however, LMP-1-positive lym-
phoma cells expressed higher levels of IRF-7 than did LMP-
1-negative cells (panel D). In addition, some IRF-7 localized in
the nucleus, sometimes predominantly, and was presumably
activated in LMP-1-expressing cells. Because LMP-1 is a
marker for CNS lymphoma, these results provide further evi-
dence that IRF-7 is highly expressed and can move into the
nucleus or be activated in CNS lymphoma cells in vivo. In
EBV-negative cells, IRF-7 expression was lower than in LMP-
1-positive cells (Fig. 4). Also, due to paraffin embedding, the
background was higher than in isolated primary B cells (com-
pare Fig. 2 and 4). Thus, the subcellular localization of IRF-7
in LMP-1-negative cells is hardly conclusive. In addition, due
to the fact that LMP-1 is a marker for CNS lymphoma, we
cannot be certain that the LMP-1-negative cells were actually
CNS lymphomas without another credible tumor marker.
Based on the subcellular localization of IRF-7 in primary B
cells (Fig. 2A) and confocal imaging of the CNS lymphoma
specimens, IRF-7 is likely localized in the cytoplasm in LMP-
1-negative cells. Thus, by using immunohistological staining as
well as confocal imaging, we concluded that IRF-7 is highly
expressed in EBV-positive CNS lymphoma cells and, further-
more, that some IRF-7 is activated, i.e., localized in the nu-
cleus, in LMP-1-positive lymphoma cells.
IRF-7 causes anchorage-independent growth in NIH 3T3
cells. The foregoing data suggest that IRF-7 may be a mediator
for EBV, or LMP-1 in particular, during the transformation
process. Because some IRFs are known to have oncogenic
potential, whether IRF-7 has similar properties was evaluated
by use of the in vitro transformation assay system used to
evaluate other IRF members. We first examined whether
IRF-7 is capable of transforming NIH 3T3 mouse fibroblasts.
An IRF-7 plasmid was transfected into NIH 3T3 cells, and the
IRF-7-expressing cells were selected in G418-containing me-
dium. Stable cell lines were pooled, and the expression of
IRF-7 was confirmed by immunoprecipitation and Western
blot analyses (Fig. 5B). IRF-7 has several splicing forms. For
this work, we used an expression plasmid for the full-length
IRF-7A because it is the major form, at least in lymphocytes
(60). As shown in Fig. 5, IRF-7 could induce the growth of
NIH 3T3 cells in soft agar. These data indicate that IRF-7 has
transforming activity in cell culture.
IRF-7-expressing NIH 3T3 cells cause tumor formation in
nude mice. The induction of anchorage-independent growth by
IRF-7 in NIH 3T3 cells raised the possibility that IRF-7 might
have oncogenic potential. We further tested whether IRF-7-
expressing NIH 3T3 cells are capable of inducing tumor for-
mation in vivo. Cells from the parental NIH 3T3 cell lines, the
empty pcDNA3 (neo) vector control, and pcDNA-IRF-
7A(neo)-transfected cells (106 cells) were injected subcutane-
ously into the flanks of athymic (nu/nu) mice, and the appear-
ance of tumor formation was monitored every 2 weeks. As
shown in Table 2, the IRF-7-expressing cells were capable of
inducing tumor formation. In addition, IRF-7 continued to be
expressed in the tumors growing in the mice (Fig. 6B). It
should be noted that human IRF-7 (hIRF-7) and mouse IRF-7
(mIRF-7) have different molecular masses (69 versus 46 kDa)
and can thus be distinguished. Also, the IRF-7 expressed in
these tumor-derived cells was predominantly localized in the
cytoplasm, as determined by immunostaining (data not
shown); however, we could not readily distinguish the signal
derived from the endogenous mIRF-7 from that derived from
the ectopically expressed hIRF-7 with the available antibodies.
IRF-7 and LMP-1 have an additive effect on anchorage-
independent growth of NIH 3T3 cells. Because the expression
of LMP-1 and IRF-7 seemed to be closely associated in human
CNS lymphomas in vivo (Fig. 4), we examined whether LMP-1
and IRF-7 might have synergistic effects. IRF-7, with or with-
out the LMP-1 plasmid, was transfected, and stably expressing
clones were pooled and assayed for anchorage-independent
FIG. 3. Histological and immunohistochemical characterization
and expression of LMP and IRF-7 in CNS lymphomas. Hematoxylin
and eosin (H.E.) staining of a CNS lymphoma demonstrated the
perivascular concentric accumulation of neoplastic cells (A). At a
higher magnification, the tumors were seen to be composed of numer-
ous homogeneous round cells with atypical nuclei and a scant cyto-
plasm (B). Immunohistochemistry for the pan-B-cell marker CD20
highlighted the neoplastic lymphocytes in the Virchow-Robin space
(C) as well as neoplastic lymphocytes infiltrating the brain parenchyma
(D). The latent membrane protein (LMP-1) of EBV was robustly
expressed in the cytoplasm of neoplastic lymphocytes in both the
perivascular space and the brain parenchyma (E and F, respectively).
Finally, the expression of IRF-7 was detected in numerous neoplastic
lymphocytes (G and H, respectively). The original magnifications of
the images and the identities of the proteins are indicated.
VOL. 78, 2004 IRF-7 AND EBV TRANSFORMATION 12991
 
growth. As shown in Fig. 7, LMP-1 and IRF-7 had an additive
and possibly cooperative, but not synergistic, effect on the
anchorage-independent growth of NIH 3T3 cells. LMP-1 itself
also caused cellular transformation, as reported previously (11,
49, 50). It should be mentioned that the additive or cooperative
effect of LMP-1 and IRF-7 was apparent only in the in vitro
situation, since a corresponding effect has not been observed
for the tumor formation assay with nude mice in vivo (data not
shown). Possible explanations include the fact that LMP-1
itself is a strong inducer of tumors in mice and needs only 3
weeks for tumor formation; however, IRF-7 may need up to 2
months for tumor formation. In addition, NIH 3T3 cells ex-
press endogenous murine IRF-7 that may be activated by
LMP-1.
DISCUSSION
The unique characteristic of EBV as a human virus is its
ability to immortalize and transform primary human B cells in
vitro. LMP-1 is the principal oncoprotein required for immor-
talization and transformation. In addition, the expression of
LMP-1 in nasopharyngeal carcinomas, AIDS-associated CNS
lymphomas, and posttransplantation lymphoproliferative dis-
orders is consistent. Because in lymphomas immortalization
FIG. 4. IRF-7 is expressed and localized in the nuclei of LMP-1-expressing CNS lymphoma cells. A CNS lymphoma specimen was stained with
IRF-7 (rabbit) and LMP-1 (mouse) antibodies. Cy5- and Cy2-labeled secondary antibodies were used to distinguish the signals from IRF-7 and
LMP-1, respectively. Propidium iodide was used to stain the nuclei. The colors were artificially mounted to facilitate viewing. Blue, nuclei; green,
LMP-1; red, IRF-7. (A) IRF-7 signal only; (B) LMP-1 signal only; (C) LMP-1 plus IRF-7 signals; (D) LMP-1, IRF-7, and nucleus signals are mixed.
FIG. 5. IRF-7 causes anchorage-independent growth of NIH 3T3 cells. (A) A soft-agar assay was used for an IRF-7 stably expressing cell line
established in NIH 3T3 cells. The numbers are averages from two experiments. (B) Expression of IRF-7 in NIH 3T3 cells, as determined by
immunoprecipitation followed by Western blotting with an IRF-7 antibody.
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takes place in cells lacking genetic mutations acquired during
cell culture, at least initially, LMP-1 must contribute to cellular
transformation by altering the expression and activity of cellu-
lar genes that are involved in oncogenesis.
One of the genes regulated by LMP-1 is IRF-7. Some IRFs
are already known to have oncogenic properties. IRF-2 and
IRF-4 are considered oncogenes, and IRF-4 has been impli-
cated in multiple myelomas because a chromosomal translo-
cation of the IRF-4 gene was found in some of these neoplasms
(14, 27, 44, 46). HHV-8 vIRF1 is apparently also oncogenic, as
shown by the transformation of NIH 3T3 cells and tumor
formation in nude mice (9).
IRF-7 may contribute to oncogenesis by LMP-1. First, IRF-7
itself has oncogenic potential, as shown by its ability to cause
anchorage-independent growth in NIH 3T3 cells as well as to
induce tumors in nude mice (Fig. 5 and 6). These data suggest
that the expression of IRF-7 per se is able to transform 3T3
cells. It is interesting that IRF-7 exists in at least two forms, an
activated and an inactivated form. LMP-1-activated IRF-7 is a
phosphoprotein and is localized to the nucleus (58). However,
IRF-7 itself is also a phosphoprotein, and trace amounts are
localized to the nucleus even in the absence of LMP-1. Trace
amounts of activated IRF-7 can be detected when IRF-7 is
FIG. 6. IRF-7 causes tumor formation in nude mice. (A) IRF-7-expressing cells induce tumors. A tumor in the flank of a nude mouse injected
with IRF-7-expressing cells is shown. (B) Tumors express IRF-7. Cell lysates from the IRF-7-derived tumors were analyzed by Western blotting
with an IRF-7 antibody. The positive control was a cell lysate from Jijoye cells. (C and D) Paraffin sections from IRF-7-containing tumors were
stained with hematoxylin and eosin and viewed at magnifications of 40 and 100, respectively.
FIG. 7. IRF-7 and LMP-1 have an additive effect on anchorage-
independent growth of NIH 3T3 cells. Soft-agar assays were used for
a stably expressing cell line established in NIH 3T3 cells. The colony
numbers are averages from two experiments.
TABLE 2. IRF-7 causes tumor formation in nude micea
Expt or cell type
Tumor formation (no. of mice with tumors/
total no. of mice)
1 month 2 months 3 months
1
Parental (NIH 3T3) 0/3 0/3 0/3
Vector (pcDNA3) 0/3 0/3 1/3
IRF-7A 0/3 2/3 3/3
2
Parental (NIH 3T3) 0/8 0/8
Vector (pcDNA3) 0/8 1/8
IRF-7A 0/8 8/8
a Nude mice were injected with parental cells (NIH 3T3) or IRF-7-expressing
cells (IRF-7A) or a vector control cell line (pcDNA3). The numbers of mice with
tumors were counted at the indicated times.
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overexpressed (19, 23, 58). Although the exact nature of acti-
vated IRF-7 is unknown, our data do not eliminate the possi-
bility that these trace amounts contribute to or are even re-
sponsible for the oncogenic properties of IRF-7. Our data
show that (i) LMP-1 and IRF-7 have a cooperative or at least
an additive effect on transformation (Fig. 7) which may be
related to the activation processes of IRF-7 (58) and (ii) IRF-7
can activate the EBV LMP-1 promoter and increase the ex-
pression of LMP-1 (29). Because IRF-7 is expressed in human
B cells (Fig. 1 and 2), these data provide evidence that IRF-7
may contribute to the transformation capability of LMP-1 di-
rectly by a cooperative (or additive) functional interaction with
LMP-1 or indirectly by the induction of LMP-1.
One possible mechanism whereby IRF-7 transforms 3T3
cells is by acting like IRF-2, which blocks the functions of
IRF-1, a putative tumor suppressor gene (46). The mechanism
used by IRF-2 to transform cells is to compete with IRF-1 for
DNA binding, thus disrupting the tumor suppressor function
of IRF-1. The ratio of IRF-1 to IRF-2 is thought to be impor-
tant for tumor development (27, 45, 53). IRF-7 also competes
with IRF-1 for DNA binding, at least in vitro (60). The same
competition between the two IRFs may also occur in vivo,
especially when IRF-7 is activated. A similar mechanism might
also apply to the transformation of rodent cells by IRF-7. It is
noteworthy that the ratios of IRF-1 to IRF-2 are similar for
primary B cells and EBV-transformed B cells; however, the
ratios of IRF-1 to IRF-7 are drastically changed during the
transformation process (Fig. 1). Thus, one possible mechanism
for EBV oncogenesis is that IRF-7, which is induced by
LMP-1, modifies the genes that are regulated by the putative
tumor suppressor gene IRF-1. It should be stressed that IRF-7
may use additional mechanisms for transformation.
IRF-7 may play a role in EBV-associated tumors. One ma-
lignancy that is believed to be caused by EBV is CNS lym-
phoma in immunocompromised hosts. EBV establishes type
III latency with LMP-1 expression in these B-lymphoma cells.
The cells are phenotypically similar to in vitro-transformed
LCLs. We have shown that the expression and activation of
IRF-7 are associated with the EBV immortalization and trans-
formation process in vitro (Fig. 1 and 2). Furthermore, for
CNS lymphoma cells, the association between high levels of
LMP-1 and IRF-7 is highly significant (Table 1). IRF-7 is
expressed and activated in LMP-1-expressing CNS lymphoma
cells in vivo (Table 1; Fig. 3 and 4). The cooperative activity by
LMP-1 and IRF-7 may contribute to the oncogenesis of at least
some CNS lymphomas (Table 1; Fig. 3, 4, and 7). Moreover,
IRF-7 can induce the LMP-1 promoter, and the activation of
IRF-7 may enhance this induction (29). This circuit may po-
tentiate LMP-1’s activity in vivo by enhancing its expression
(29).
The data strongly support the contention that IRF-7 expres-
sion in human cancer is meaningful and suggest that nuclear
IRF-7 is relevant to viral transformation. However, whether
activated IRF-7 is an effector in cellular transformation, espe-
cially if it is triggered by LMP-1, remains to be determined. It
should be noted that posttranslationally activated proteins can
have oncogenic roles. A well-characterized example is the ac-
tivated STAT-3 protein, which plays essential roles in cellular
transformation and the growth of cancer cells (3).
Generally, the transformation of a cell requires multiple
molecular events (6, 15, 18, 36, 40). LMP-1 is an oncogenic
protein that is required for the transformation of primary B
cells in vitro and is believed to drive the EBV transformation
process in vivo. LMP-1, through its signaling from the cell
membrane, activates a variety of cellular genes involved in cell
proliferation, apoptosis, angiogenesis, immune regulation, and
signal transduction, to which may now be added IRF-7, that
collectively transform and enhance the malignant potential of
cells (4, 5, 7, 13, 25, 47–49, 51, 54).
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